Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir

Affiliations

¹ Department of Medicine Solna Unit for Experimental Medicine Cell and Molecular Immunology, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.

Comment

Cecilia Söderberg-Naucler et al. Int J Cancer. 2014.

. 2014 Jul 1;135(1):248-9.

doi: 10.1002/ijc.28663. Epub 2014 Jan 6.

¹ Department of Medicine Solna Unit for Experimental Medicine Cell and Molecular Immunology, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.

No abstract available

Comment on

Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, Bjurman B, Tammik C, Skarman P, Peredo I, Söderberg-Nauclér C. Stragliotto G, et al. Int J Cancer. 2013 Sep 1;133(5):1204-13. doi: 10.1002/ijc.28111. Epub 2013 Mar 13. Int J Cancer. 2013. PMID: 23404447 Clinical Trial.
Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?
Liu CJ, Hu YW. Liu CJ, et al. Int J Cancer. 2014 Jul 1;135(1):250-1. doi: 10.1002/ijc.28664. Epub 2014 Jan 6. Int J Cancer. 2014. PMID: 24338590 No abstract available.